These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

204 related articles for article (PubMed ID: 15994085)

  • 1. Inhibition of the severe acute respiratory syndrome 3CL protease by peptidomimetic alpha,beta-unsaturated esters.
    Shie JJ; Fang JM; Kuo TH; Kuo CJ; Liang PH; Huang HJ; Wu YT; Jan JT; Cheng YS; Wong CH
    Bioorg Med Chem; 2005 Sep; 13(17):5240-52. PubMed ID: 15994085
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The newly emerged SARS-like coronavirus HCoV-EMC also has an "Achilles' heel": current effective inhibitor targeting a 3C-like protease.
    Ren Z; Yan L; Zhang N; Guo Y; Yang C; Lou Z; Rao Z
    Protein Cell; 2013 Apr; 4(4):248-50. PubMed ID: 23549610
    [No Abstract]   [Full Text] [Related]  

  • 3. Liquid chromatography-mass spectrometry and liquid chromatography-NMR characterization of in vitro metabolites of a potent and irreversible peptidomimetic inhibitor of rhinovirus 3C protease.
    Zhang KE; Hee B; Lee CA; Liang B; Potts BC
    Drug Metab Dispos; 2001 May; 29(5):729-34. PubMed ID: 11302940
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cinanserin is an inhibitor of the 3C-like proteinase of severe acute respiratory syndrome coronavirus and strongly reduces virus replication in vitro.
    Chen L; Gui C; Luo X; Yang Q; Günther S; Scandella E; Drosten C; Bai D; He X; Ludewig B; Chen J; Luo H; Yang Y; Yang Y; Zou J; Thiel V; Chen K; Shen J; Shen X; Jiang H
    J Virol; 2005 Jun; 79(11):7095-103. PubMed ID: 15890949
    [TBL] [Abstract][Full Text] [Related]  

  • 5. New developments for the design, synthesis and biological evaluation of potent SARS-CoV 3CL(pro) inhibitors.
    Regnier T; Sarma D; Hidaka K; Bacha U; Freire E; Hayashi Y; Kiso Y
    Bioorg Med Chem Lett; 2009 May; 19(10):2722-7. PubMed ID: 19362479
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluation of metal-conjugated compounds as inhibitors of 3CL protease of SARS-CoV.
    Hsu JT; Kuo CJ; Hsieh HP; Wang YC; Huang KK; Lin CP; Huang PF; Chen X; Liang PH
    FEBS Lett; 2004 Sep; 574(1-3):116-20. PubMed ID: 15358550
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Development of a red-shifted fluorescence-based assay for SARS-coronavirus 3CL protease: identification of a novel class of anti-SARS agents from the tropical marine sponge Axinella corrugata.
    Hamill P; Hudson D; Kao RY; Chow P; Raj M; Xu H; Richer MJ; Jean F
    Biol Chem; 2006 Aug; 387(8):1063-74. PubMed ID: 16895476
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Severe acute respiratory syndrome coronavirus papain-like novel protease inhibitors: design, synthesis, protein-ligand X-ray structure and biological evaluation.
    Ghosh AK; Takayama J; Rao KV; Ratia K; Chaudhuri R; Mulhearn DC; Lee H; Nichols DB; Baliji S; Baker SC; Johnson ME; Mesecar AD
    J Med Chem; 2010 Jul; 53(13):4968-79. PubMed ID: 20527968
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dissection study on the severe acute respiratory syndrome 3C-like protease reveals the critical role of the extra domain in dimerization of the enzyme: defining the extra domain as a new target for design of highly specific protease inhibitors.
    Shi J; Wei Z; Song J
    J Biol Chem; 2004 Jun; 279(23):24765-73. PubMed ID: 15037623
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Peptidomimetic ethyl propenoate covalent inhibitors of the enterovirus 71 3C protease: a P2-P4 study.
    Ang MJ; Lau QY; Ng FM; Then SW; Poulsen A; Cheong YK; Ngoh ZX; Tan YW; Peng J; Keller TH; Hill J; Chu JJ; Chia CS
    J Enzyme Inhib Med Chem; 2016; 31(2):332-9. PubMed ID: 25792507
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Structure-assisted design of mechanism-based irreversible inhibitors of human rhinovirus 3C protease with potent antiviral activity against multiple rhinovirus serotypes.
    Matthews DA; Dragovich PS; Webber SE; Fuhrman SA; Patick AK; Zalman LS; Hendrickson TF; Love RA; Prins TJ; Marakovits JT; Zhou R; Tikhe J; Ford CE; Meador JW; Ferre RA; Brown EL; Binford SL; Brothers MA; DeLisle DM; Worland ST
    Proc Natl Acad Sci U S A; 1999 Sep; 96(20):11000-7. PubMed ID: 10500114
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Rapid peptide-based screening on the substrate specificity of severe acute respiratory syndrome (SARS) coronavirus 3C-like protease by matrix-assisted laser desorption/ionization time-of-flight mass spectrometry.
    Chu LH; Choy WY; Tsai SN; Rao Z; Ngai SM
    Protein Sci; 2006 Apr; 15(4):699-709. PubMed ID: 16600962
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In vitro antiviral activity of AG7088, a potent inhibitor of human rhinovirus 3C protease.
    Patick AK; Binford SL; Brothers MA; Jackson RL; Ford CE; Diem MD; Maldonado F; Dragovich PS; Zhou R; Prins TJ; Fuhrman SA; Meador JW; Zalman LS; Matthews DA; Worland ST
    Antimicrob Agents Chemother; 1999 Oct; 43(10):2444-50. PubMed ID: 10508022
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Structural basis for antiviral inhibition of the main protease, 3C, from human enterovirus 93.
    Costenaro L; Kaczmarska Z; Arnan C; Janowski R; Coutard B; Solà M; Gorbalenya AE; Norder H; Canard B; Coll M
    J Virol; 2011 Oct; 85(20):10764-73. PubMed ID: 21835784
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Stable benzotriazole esters as mechanism-based inactivators of the severe acute respiratory syndrome 3CL protease.
    Wu CY; King KY; Kuo CJ; Fang JM; Wu YT; Ho MY; Liao CL; Shie JJ; Liang PH; Wong CH
    Chem Biol; 2006 Mar; 13(3):261-8. PubMed ID: 16638531
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Structure-based design, synthesis, and biological evaluation of irreversible human rhinovirus 3C protease inhibitors. 4. Incorporation of P1 lactam moieties as L-glutamine replacements.
    Dragovich PS; Prins TJ; Zhou R; Webber SE; Marakovits JT; Fuhrman SA; Patick AK; Matthews DA; Lee CA; Ford CE; Burke BJ; Rejto PA; Hendrickson TF; Tuntland T; Brown EL; Meador JW; Ferre RA; Harr JE; Kosa MB; Worland ST
    J Med Chem; 1999 Apr; 42(7):1213-24. PubMed ID: 10197965
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Discovery of potent anilide inhibitors against the severe acute respiratory syndrome 3CL protease.
    Shie JJ; Fang JM; Kuo CJ; Kuo TH; Liang PH; Huang HJ; Yang WB; Lin CH; Chen JL; Wu YT; Wong CH
    J Med Chem; 2005 Jun; 48(13):4469-73. PubMed ID: 15974598
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The enterovirus protease inhibitor rupintrivir exerts cross-genotypic anti-norovirus activity and clears cells from the norovirus replicon.
    Rocha-Pereira J; Nascimento MS; Ma Q; Hilgenfeld R; Neyts J; Jochmans D
    Antimicrob Agents Chemother; 2014 Aug; 58(8):4675-81. PubMed ID: 24890597
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ligand-induced Dimerization of Middle East Respiratory Syndrome (MERS) Coronavirus nsp5 Protease (3CLpro): IMPLICATIONS FOR nsp5 REGULATION AND THE DEVELOPMENT OF ANTIVIRALS.
    Tomar S; Johnston ML; St John SE; Osswald HL; Nyalapatla PR; Paul LN; Ghosh AK; Denison MR; Mesecar AD
    J Biol Chem; 2015 Aug; 290(32):19403-22. PubMed ID: 26055715
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Coronavirus main proteinase (3CLpro) structure: basis for design of anti-SARS drugs.
    Anand K; Ziebuhr J; Wadhwani P; Mesters JR; Hilgenfeld R
    Science; 2003 Jun; 300(5626):1763-7. PubMed ID: 12746549
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.